Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.

To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
ABA White Collar Crime Institute 2026
Speaking Engagement
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
CLA Antitrust and Consumer Protection Section In-House Counsel Summit
Speaking Engagement
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
DOJ’s First Antitrust Whistleblower Payout Signals a New Enforcement Playbook
Axinn Viewpoints
Antitrust
First Whistleblower Reward Sparks Race to Report, Lawyers Say
Media Mentions
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Healthcare Antitrust Year-In-Review Webinar
Webinar
Antitrust
Antitrust Becoming a Go-To Play in Junior College Athletes' Playbooks
Axinn Viewpoints
Antitrust

